PDF factsheet

antithrombotics in thrombosis prevention for elective major knee surgery , clinical trials results

apixaban versus enoxaparin (europe regimen)
ADVANCE 2, 2010 NCT00452530	apixaban 2.5mg twice daily during 12 days versus enoxaparin 40mg once daily 12 days	patients undergoing elective unilateral or bilateral total knee replacement	double blind Follow-up duration: 12 days 27 countries
apixaban versus enoxaparin (US regimen)
APROPOS 2.5mg, 2007 NCT00097357	apixaban 2.5mg BID for 12 days versus enoxaparin 30mg twice daily for 12 days	patients undergoing elective total knee replacement surgery	double blind Follow-up duration: 12 days
ardeparin versus placebo
Levine, 1996	ardeparin 50/kgx2 +elastic stockings versus Placebo+elastic stockings	Knee	double blind Follow-up duration: 14 days
Aspirin versus placebo
McKenna-I, 1980	Aspirin 975mg or 3900mg daily versus placebo	total knee replacement	double-blind Follow-up duration: 2 weeks
dabigatran 150mg versus enoxaparin (europe regimen)
RE-MODEL (150mg), 2007	dabigatran etexilate 150 mg q.d. for 6-10 days versus Enoxaparin 40 mg q.d. for 6-10 days	Total knee replacement	double blind Follow-up duration: 6-10 days, mean 8 days Europe, Australia, South Africa
dabigatran 150mg versus enoxaparin (US regimen)
RE-MOBILIZE (150mg), 2008	dabigatran etexilate 150 mg q.d. for 12-15 days versus enoxaparin 30 mg SC BID after surgery for 12-15 days	Total knee replacement	double blind Follow-up duration: 12-15 days, median 14d US, Canada, Mexico, UK
dabigatran 220mg versus enoxaparin (europe regimen)
RE-MODEL (220mg), 2007	dabigatran etexilate 220 mg q.d. 6-10 days versus Enoxaparin 40 mg q.d. for 6-10 days	patients undergoing total knee replacement	double blind Follow-up duration: 6-10 days, mean 8 days Europe, Australia, South Africa
dabigatran 220mg versus enoxaparin (US regimen)
RE-MOBILIZE (220mg), 2008	dabigatran etexilate 220 mg for 12-15 days versus Enoxaparin 30mg SC BID after surgery for 12-15 days	Total knee replacement	double blind Follow-up duration: 12-15 days, median 14d US, Canada, Mexico, UK
enoxaparin versus placebo
Leclerc, 1991	Enoxaparin 3000 x2 versus Placebo	Knee	double blind Follow-up duration: 14 days
fondaparinux versus enoxaparin
L8635, 0	Fondaparinux 2.5mg once daily subcutaneously for 7 days versus enoxaparin 40mg once daily SC for 7 days	Taiwanese patients undergoing elective knee replacement	open, blind assessment Follow-up duration: 10 days Taiwan
PENTAMAKS (Bauer), 2001	fondaparinux 2.5-mg once-daily subcutaneous, starting 6 hours after surgery versus enoxaparin 30mg twice daily (North america recommendation)	elective major knee surgery	double blind Follow-up duration: 11 days North america
rivaroxaban versus enoxaparin (europe regimen)
RECORD 3, 2008 NCT00361894	rivaroxaban 10 mg once daily for 10- 14 days versus enoxaparin 40 mg subcutaneous once daily for 10-14 days	patients undergoing total knee arthroplasty	double blind Follow-up duration: 13-17 days 19 countries worldwide
rivaroxaban versus enoxaparin (US regimen)
ODIXa-KNEE, 2005	BAY 59-7939 5mg b.i.d. for 5–9 days versus enoxaparin 30 mg b.i.d. for 5–9 days	patients undergoing elective total knee replacement	double blind Follow-up duration: 5-9 days North America
RECORD 4, 2009 NCT00362232	rivaroxaban 10mg once daily for 10 to 14 days versus enoxaparin 30 mg twice daily by subcutaneous injection for 10-14 days	patients who had undergone total-knee-replacement surgery	double blind Follow-up duration: 40 days 12 countries
ximelagatran versus Dalteparin
METHRO I, 2002	Melagatran 1–4 mg s.c. immediately before surgery, melagatran at 20.00 hours, then ximelagatran 6–24 mg orally b.d. for 6–9 days versus Dalteparin 5000 IU o.d., started evening before surgery for 6–9 days	adults undergoing hip or knee replacement	open Follow-up duration: 6–9 days Swedish
ximelagatran versus Enoxaparin
METHRO III, 2002	Melagatran 3 mg s.c. 4–12h after surgery, then ximelagatran24 mg orally b.d. for 7–10 days versus Enoxaparin 40 mg s.c. o.d. 12 h before surgery for 7–10 days	hip or knee replacement	double-blind Follow-up duration: 8–11 days Europe, South Africa
Phase II (Heit), 2001	Ximelagatran 8, 12, 18 or 24 mgorally b.d., at least 12 h after surgery for 6–12 days versus Enoxaparin 30 mg s.c. b.d.,starting at least 12 h after surgery for 6–12 days	adults (age>18 years and weight at least 40 kg) undergoing knee replacements	double-blind Follow-up duration: 6–12 days North American
EXPRESS, 2003	Melagatran 2 mg s.c. up to 30 min before surgery, then melagatran 3 mg at least 8 hafter surgery, then ximelagatran 24 mg orally b.d. for 8–11 days versus Enoxaparin 40 mg s.c. o.d.,starting 12 h before surgery for 8–11 days	hip or knee replacement	double-blind Follow-up duration: 8–11 days Europe

Options

Group by
in first

in second

Order trials by

Filter

display ongoing trials

Type of trial

Limit to tags

Exclude tags